WealthTrust Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

WealthTrust Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,697	Closed	-$213K	–	81
2021 Q3	$213K	Sell	1,697 -60	-3%	-$7.73K	0.19%	63
2021 Q2	$238K	Buy	+1,757	New	+$231K	0.21%	65

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

WealthTrust Asset Management's XBI Position: Q4 2021 in Review

WealthTrust Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2021, closing a stake of 1,697 shares — an estimated $213K sold.

WealthTrust Asset Management first reported a position in XBI in Q2 2021 and held it in 2 quarters. The position peaked at $238K in Q2 2021. 702 funds tracked by Wall St. Rank hold XBI as of Q4 2021.

WealthTrust Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2021 after selling out during the quarter.
WealthTrust Asset Management sold 1,697 State Street SPDR S&P Biotech ETF shares in Q4 2021, an estimated $213K.
WealthTrust Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 2 quarters.
WealthTrust Asset Management's State Street SPDR S&P Biotech ETF position peaked at $238K in Q2 2021.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2021.

Based on WealthTrust Asset Management's 13F filing for Q4 2021, filed 27 May 2022.